[go: up one dir, main page]

WO2025027579A3 - Compositions d'arn ciblant le vih - Google Patents

Compositions d'arn ciblant le vih Download PDF

Info

Publication number
WO2025027579A3
WO2025027579A3 PCT/IB2024/057481 IB2024057481W WO2025027579A3 WO 2025027579 A3 WO2025027579 A3 WO 2025027579A3 IB 2024057481 W IB2024057481 W IB 2024057481W WO 2025027579 A3 WO2025027579 A3 WO 2025027579A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeting hiv
rna compositions
compositions targeting
present disclosure
disclosure provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/057481
Other languages
English (en)
Other versions
WO2025027579A2 (fr
Inventor
Valentin LE DOUCE
Felix TOLKSDORF
Johannes NELKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of WO2025027579A2 publication Critical patent/WO2025027579A2/fr
Publication of WO2025027579A3 publication Critical patent/WO2025027579A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente divulgation concerne des compositions (par exemple, des compositions pharmaceutiques) pour l'administration d'agents d'anticorps anti-VIH et des technologies associées (par exemple, des constituants de ceux-ci et/ou des procédés associés). Entre autres, la présente divulgation concerne des polyribonucléotides codant pour une chaîne d'immunoglobuline d'un agent anticorps anti-VIH.
PCT/IB2024/057481 2023-08-03 2024-08-01 Compositions d'arn ciblant le vih Pending WO2025027579A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363517596P 2023-08-03 2023-08-03
US63/517,596 2023-08-03

Publications (2)

Publication Number Publication Date
WO2025027579A2 WO2025027579A2 (fr) 2025-02-06
WO2025027579A3 true WO2025027579A3 (fr) 2025-03-06

Family

ID=92711095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/057481 Pending WO2025027579A2 (fr) 2023-08-03 2024-08-01 Compositions d'arn ciblant le vih

Country Status (1)

Country Link
WO (1) WO2025027579A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070776A1 (fr) * 2011-11-07 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps neutralisant la gp41 et leur utilisation
WO2016196975A1 (fr) * 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Anticorps neutralisants dirigés contre la protéine d'enveloppe (env) du vih-1 et leur utilisation
WO2017186928A1 (fr) * 2016-04-29 2017-11-02 Curevac Ag Arn codant pour un anticorps
WO2018067580A1 (fr) * 2016-10-03 2018-04-12 Duke University Procédés d'identification d'immunogènes par ciblage de mutations improbables
WO2018232355A1 (fr) * 2017-06-15 2018-12-20 Modernatx, Inc. Anticorps d'arn
US20200399369A1 (en) * 2019-04-09 2020-12-24 Sanofi Trispecific binding proteins, methods, and uses thereof
US20210087259A1 (en) * 2013-12-02 2021-03-25 The Trustees Of Columbia University In The City Of New York Bispecific hiv-1-neutralizing antibodies

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP3556323B2 (ja) 1995-06-15 2004-08-18 富士通株式会社 中継装置
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
WO1998050431A2 (fr) 1997-05-02 1998-11-12 Genentech, Inc. Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
CA2321837C (fr) 1998-02-03 2011-08-16 Inex Pharmaceuticals Corporation Administration systemique de particules lipidiques du plasmide stables dans le serum en cancerotherapie
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
EP2338478B1 (fr) 2002-06-28 2014-07-23 Protiva Biotherapeutics Inc. Méthode de préparation de liposomes
CA2532228C (fr) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Arn interferant encapsule dans un lipide
US6927663B2 (en) 2003-07-23 2005-08-09 Cardiac Pacemakers, Inc. Flyback transformer wire attach method to printed circuit board
WO2005026372A1 (fr) 2003-09-15 2005-03-24 Protiva Biotherapeutics, Inc. Composes conjugues lipidiques polyethyleneglycol-dialkyloxypropyle et utilisations de ces composes
ATE536418T1 (de) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
EP1781593B1 (fr) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Lipides cationiques et leurs procédés d'utilisation
CA2616877C (fr) 2005-07-27 2014-01-28 Protiva Biotherapeutics, Inc. Systemes et procedes de fabrication de liposomes
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
CA3044134A1 (fr) 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Compositions et procedes ameliores pour la delivrance d'acides nucleiques
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
KR102760023B1 (ko) 2008-11-10 2025-01-31 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
WO2011000106A1 (fr) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Lipides cationiques et procédés améliorés pour l'administration d'agents thérapeutiques
WO2011066651A1 (fr) 2009-12-01 2011-06-09 Protiva Biotherapeutics, Inc. Préparations de snalp contenant des antioxydants
EP3296398A1 (fr) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Nanoparticules pour l'administration d'acide nucléique
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
EP3254672B1 (fr) 2010-06-03 2025-08-20 Alnylam Pharmaceuticals, Inc. Lipides biodégradables pour l'administration d'agents actifs
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
EP2663548B1 (fr) 2011-01-11 2017-04-05 Alnylam Pharmaceuticals, Inc. Lipides pégylés et leur utilisation pour une administration de médicament
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
WO2013016058A1 (fr) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Nouveaux lipides cationiques contenant du bis-azote pour administration d'oligonucléotide
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
US8762704B2 (en) 2011-09-29 2014-06-24 Apple Inc. Customized content for electronic devices
WO2013086322A1 (fr) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipides biodégradables ramifiés à terminaisons alkyle et cycloalkyle destinés à l'administration d'agents actifs
CA2856742A1 (fr) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipides biodegradables pour l'administration d'agents actifs
WO2013086373A1 (fr) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipides pour l'administration d'agents actifs
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
EP3071547B1 (fr) 2013-11-18 2024-07-10 Arcturus Therapeutics, Inc. Lipides cationiques ionisables pour la delivrance d'arn
CN111057147B (zh) 2014-01-06 2023-11-10 豪夫迈·罗氏有限公司 单价血脑屏障穿梭模块
HRP20221536T1 (hr) 2014-06-25 2023-02-17 Acuitas Therapeutics Inc. Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
WO2016005004A1 (fr) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilisation de séquences d'adn codant pour une séquence poly (a)
WO2016176330A1 (fr) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Arn à nucléoside modifié destiné à induire une réponse immunitaire adaptative
EP3313829B1 (fr) 2015-06-29 2024-04-10 Acuitas Therapeutics Inc. Formulations de lipides et de nanoparticules de lipides pour l'administration d'acides nucléiques
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
WO2017055539A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps multispécifiques
WO2017059902A1 (fr) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh Séquences utr 3' permettant la stabilisation d'arn
WO2018081480A1 (fr) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Formulations de nanoparticules lipidiques
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2016349392B2 (en) 2015-11-03 2023-07-13 The Trustees Of Columbia University In The City Of New York Neutralizing antibodies to HIV-1 gp41 and their use
AU2017251983B2 (en) 2016-04-22 2023-07-20 BioNTech SE Methods for providing single-stranded RNA
JP2022530018A (ja) 2019-04-26 2022-06-27 ジェネヴァント サイエンシズ ゲーエムベーハー 脂質ナノ粒子
WO2021001023A1 (fr) 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Formulations d'arn appropriées pour une thérapie
CN115811986A (zh) 2020-04-22 2023-03-17 生物技术欧洲股份公司 冠状病毒疫苗

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070776A1 (fr) * 2011-11-07 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps neutralisant la gp41 et leur utilisation
US20210087259A1 (en) * 2013-12-02 2021-03-25 The Trustees Of Columbia University In The City Of New York Bispecific hiv-1-neutralizing antibodies
WO2016196975A1 (fr) * 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Anticorps neutralisants dirigés contre la protéine d'enveloppe (env) du vih-1 et leur utilisation
WO2017186928A1 (fr) * 2016-04-29 2017-11-02 Curevac Ag Arn codant pour un anticorps
WO2018067580A1 (fr) * 2016-10-03 2018-04-12 Duke University Procédés d'identification d'immunogènes par ciblage de mutations improbables
WO2018232355A1 (fr) * 2017-06-15 2018-12-20 Modernatx, Inc. Anticorps d'arn
US20200399369A1 (en) * 2019-04-09 2020-12-24 Sanofi Trispecific binding proteins, methods, and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MORITZ THRAN ET AL: "mRNA mediates passive vaccination against infectious agents, toxins, and tumors", EMBO MOLECULAR MEDICINE (ONLINE), vol. 9, no. 10, 9 August 2017 (2017-08-09), DE, pages 1434 - 1447, XP055505303, ISSN: 1757-4684, DOI: 10.15252/emmm.201707678 *
NORBERT PARDI ET AL: "Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge", NATURE COMMUNICATIONS, vol. 8, 2 March 2017 (2017-03-02), pages 14630, XP055557652, DOI: 10.1038/ncomms14630 *
R. S. RUDICELL ET AL: "Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo", JOURNAL OF VIROLOGY, vol. 88, no. 21, 1 November 2014 (2014-11-01), pages 12669 - 12682, XP055204515, ISSN: 0022-538X, DOI: 10.1128/JVI.02213-14 *
YOUNG D KWON ET AL: "Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design", JOURNAL OF VIROLOGY, 1 July 2016 (2016-07-01), United States, pages 5899 - 5914, XP055341711, Retrieved from the Internet <URL:http://jvi.asm.org/content/90/13/5899.full.pdf> DOI: 10.1128/JVI.03246-15 *

Also Published As

Publication number Publication date
WO2025027579A2 (fr) 2025-02-06

Similar Documents

Publication Publication Date Title
WO2022032006A9 (fr) Molécules de liaison à l&#39;il2rb et leurs procédés d&#39;utilisation
WO2021212049A3 (fr) Anticorps monoclonaux anti-sars-cov-2
WO2021178749A3 (fr) Agents anti-ccr8
WO2021262826A3 (fr) Analogues de 1&#39;-cyano nucléoside et leurs utilisations
WO2006138315A3 (fr) Formulation d&#39;anticorps stable
PE20030065A1 (es) Metodos para administrar anticuerpos anti-tnfalfa
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
WO2021207433A3 (fr) Épitopes d&#39;anticorps neutralisant le sars-cov-2
SA523451582B1 (ar) Ccr8 الأجسام المضادة لـ
MX2022014852A (es) Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2.
WO2024081729A3 (fr) Constructions de protéines de liaison lrrc-15 et leurs utilisations
WO2022032073A3 (fr) Modulateurs de trpml
WO2023044483A3 (fr) Compositions et procédés pour le traitement du cancer positif her2
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
MX2024014492A (es) Composiciones de arn para la administracion de antigenos de viruela simica y metodos relacionados
WO2023240082A3 (fr) Polythérapie associant un agent actif anti-pd-1, un agent actif anti-tim-3 et agent actif anti-lag-3 pour le traitement du cancer
WO2025027576A3 (fr) Compositions d&#39;arn ciblant le vih
WO2025027579A3 (fr) Compositions d&#39;arn ciblant le vih
EA200501341A1 (ru) Противобактериальные индолоноксазолидиноны, промежуточные соединения для их получения и содержащие их фармацевтические композиции
MX2023004533A (es) Formulaciones de anticuerpos anti-siglec-8.
WO2020214220A3 (fr) Systèmes cannabinoïdes et procédés : solubilité dans l&#39;eau, ciblage et augmentation
WO2023064612A3 (fr) Compositions pharmaceutiques pour l&#39;administration d&#39;antigènes viraux et méthodes associées
MX2025001042A (es) Formulaciones de anticuerpos contra tl1a
MA48903B1 (fr) Systèmes de résine époxy
WO2024220937A3 (fr) Agents de dégradation de tyk2 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24768379

Country of ref document: EP

Kind code of ref document: A2